(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 25 September 2008 (25.09.2008)

(51) International Patent Classification: A61K 39/395 (2006.01) A61P 19/08 (2006.01) A61P 19/10 (2006.01)

(21) International Application Number:

PCT/US2008/056527

(22) International Filing Date: 11 March 2008 (11.03.2008)

(25) Filing Language: **English**

(26) Publication Language: English

(30) Priority Data:

60/895,813 20 March 2007 (20.03.2007)

(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): KORYTKO. Andrew, Ihor [US/US]; 4720 Marblehead Bay Drive, Oceanside, California 92057 (US). MARQUIS, David, Matthew [US/US]; 2106 Meadowgreen Court, Encinitas, California 92024 (US). SMITH, Eric, Michael [US/US]; 10782 Charbono Terrace, San Diego, California 92131 (US). SWANSON, Barbara, Anne [US/US]; 1402 Willowspring Drive North, Encinitas, California 92024 (US).
- (74) Agents: COHEN, Charles, E. et al.; Eli Lilly And Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(10) International Publication Number WO 2008/115732 A3

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- (88) Date of publication of the international search report: 11 December 2008

(54) Title: ANTI-SCLEROSTIN ANTIBODIES

(57) Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.



INTERNATIONAL SEARCH REPORT

International application No PCT/US2008/056527

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/395 A61P19/10 A61P19/08 According to International Patent Classification (IPC) or to both national classification and IPC Minimum documentation searched (classification system followed by classification symbols) A61P A61K C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, EMBASE, WPI Data. CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. WO 2006/119107 A (UCB SA [GB]; AMGEN INC [US]; PASZTY CHRISTOPHER [US]; ROBINSON χ 1 - 17MARTYN) 9 November 2006 (2006-11-09) cited in the application p.7, 1. 18-24; p. 7, 1. 34; p. 12, 1. 22-p. 15, 1. 5; p. 19, 1. 3-p. 26, 1. 9; p. 125, 1. 23-p. 127, 1. 9; examples; p. 148-151 X WO 2006/119062 A (UCB SA [GB]; AMGEN INC 1-17 [US]; LU HSIENG SEN [US]; PASZTY CHRISTOPHER [U) 9 November 2006 (2006-11-09) p.7, 1. 18-24; p. 7, 1. 34; p. 12, 1. 22-p. 15, 1. 5; p. 19, 1. 3-p. 26, 1. 9; p. 125, 1. 23-p. 127, 1. 9; examples; p. 148-151 Χl Further documents are listed in the continuation of Box C. X See patent family annex. Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. O document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 26 September 2008 23/10/2008 Name and mailing address of the ISA/ Authorized officer European Patient Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Fax: (+31–70) 340–3016 Renggli, John

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2008/056527

······································		PCT/US2008/056527					
C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT							
Category*	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.				
,	BALINT R F ET AL: "ANTIBODY ENGINEERING BY PARSIMONIOUS MUTAGENESIS" GENE, ELSEVIER, AMSTERDAM, NL, vol. 137, no. 1, 27 December 1993 (1993-12-27), pages 109-118, XP002031537 ISSN: 0378-1119 page 110, right-hand column		1-17				
.,							
-							

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2008/056527

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 2006119107	A	09-11-2006	AR AU CA EP KR US UY	053266 A1 2006242431 A1 2607197 A1 1891101 A2 20080011420 A 2007110747 A1 29514 A1	25-04-2007 09-11-2006 09-11-2006 27-02-2008 04-02-2008 17-05-2007 30-11-2006
WO 2006119062	Α .	09-11-2006	AU CA EP US	2006242476 A1 2607276 A1 1891100 A2 2007072797 A1	09-11-2006 09-11-2006 27-02-2008 29-03-2007